Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Runben Biotechnology Co's total inventories for the quarter that ended in Mar. 2026 was ¥187 Mil. Runben Biotechnology Co's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was ¥154 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Runben Biotechnology Co's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was ¥2.70.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Runben Biotechnology Co's Days Inventory for the
three
months ended in Mar. 2026 was 128.55.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Runben Biotechnology Co's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.71.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Runben Biotechnology Co's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.58.
Runben Biotechnology Co (SHSE:603193) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Runben Biotechnology Co's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Runben Biotechnology Co's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Runben Biotechnology Co Total Inventories Related Terms
Runben Biotechnology Co Total Inventories Historical Data
* Premium members only.
The historical data trend for Runben Biotechnology Co's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Runben Biotechnology Co Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Runben Biotechnology Co (SHSE:603193) has a Total Inventories of ¥187 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Runben Biotechnology Co and its competitors.
Is Runben Biotechnology Co's Total Inventories too high?
Runben Biotechnology Co's current Total Inventories is ¥187 Mil. Overall, Runben Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Runben Biotechnology Co's Total Inventories compare to PG and CL?
Runben Biotechnology Co's Total Inventories of ¥187 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Consumer Packaged Goods company?
A good Total Inventories depends on the Consumer Packaged Goods industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Runben Biotechnology Co and its competitors. Runben Biotechnology Co's current Total Inventories is ¥187 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Runben Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Runben Biotechnology Co (SHSE:603193) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥28.24, compared to a current price of ¥21.96 — trading 22.2% below its estimated fair value. The current Total Inventories is ¥187 Mil. Runben Biotechnology Co's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Runben Biotechnology Co (SHSE:603193), the current Total Inventories is ¥187 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Runben Biotechnology Co (SHSE:603193) Overvalued in 2026?
Based on GuruFocus' analysis, Runben Biotechnology Co stock appears to be undervalued.
The current stock price of ¥21.96 is trading 22.2% below its estimated GF Value™ of ¥28.24.
GuruFocus considers Runben Biotechnology Co to be Modestly Undervalued.
Key valuation signals for SHSE:603193:
Total Inventories: ¥187 Mil
GF Value™: ¥28.24 vs. price of ¥21.96 (22.2% below fair value)
No single metric tells the full story. See the SHSE:603193 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603193 has been successfully added to your 
